QuarterlyIQ Insights · UNH
Factors
The full factor breakdown (the numbers behind each rank). The overview page shows the same reads in short form; this is the depth.
Factor signals
Each factor is a parallel diagnostic with a plain-language read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
The numbers
Over the trailing year it converted 1.92x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 50% for the rest of the cohort, n=2269).
The numbers
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
7 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The numbers
Not investment advice. As of 2026-06-09.
Earnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Why this setup
EPS estimate $0.00 → $4.85. 2 raised, 3 cut, 23 covering analysts.
1 upgrade, 0 downgrades / 30d, 6 maintained. 79% of analysts rate Buy.
8 PT revisions / 30d. Avg target 19.8% above current price.
Market and fundamentals agree. Analysts are positioned bullishly on a fundamentally strong name.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-09.